December 1, 2003Cardiovascular Drug ReviewsOpen Access

Ezetimibe: A First‐in‐Class, Novel Cholesterol Absorption Inhibitor

View Full Paper

Ask AI

Bookmark

Why the study?

Does ezetimibe, alone or in combination with statins, improve lipid profiles in patients with hypercholesterolemia?

Population

Patients with primary hypercholesterolemia, heterozygous and homozygous familial hypercholesterolemia…

Comparison

Ezetimibe monotherapy or coadministered with… vs Statin monotherapy or placebo

Design

Review

Authors

LLLeslie LipkaMerck & Co., Inc., Rahway, NJ, USA (United States)

Discussion

Member takes

Implication

Supports ezetimibe addition to low-dose statin as statin-sparing option; leaves open effects on clinical outcomes.

Structured PICO

Does ezetimibe, alone or in combination with statins, improve lipid profiles in patients with hypercholesterolemia?

Population

Patients with primary hypercholesterolemia, heterozygous and homozygous familial hypercholesterolemia, homozygous sitosterolemia, and experimental models (hypercholesterolemic dogs)

Intervention

Ezetimibe monotherapy or coadministered with statin therapy (simvastatin, atorvastatin, pravastatin, lovastatin)

Comparator

Statin monotherapy or placebo

Outcome

Reductions in low density lipoprotein cholesterol (LDL-C)surrogate

Ezetimibe provides an effective complementary lipid-lowering mechanism when coadministered with statins for patients with hypercholesterolemia.

Cite This Study

Leslie Lipka (2003) studied this question.

synapsesocial.com/papers/6a7e8cf298edf304e397365b https://doi.org/10.1111/j.1527-3466.2003.tb00123.x

View Full Paper

Ask AI

Bookmark

Ezetimibe: A First‐in‐Class, Novel Cholesterol Absorption Inhibitor

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Ezetimibe: A First‐in‐Class, Novel Cholesterol Absorption Inhibitor

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider